GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

In a late-stage clinical trial, Wegovy (semaglutide) significantly reduced liver inflammation and reversed scarring in people with the liver disease MASH. MASH is associated with obesity and type ...

Novo Nordisk's Rybelsus, a daily pill with the same properties as Ozempic, was FDA-approved for diabetes in 2019. However, its weight loss results didn't stack up to other GLP-1 drugs in studies ...

In the STEP UP trial, the higher dose of Wegovy ® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to ...